Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lazard, Inc. Common Stock (NY:LAZ)

49.79 -1.13 (-2.22%)
Official Closing Price Updated: 6:30 PM EDT, Oct 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Lazard, Inc. Common Stock

< Previous 1 2 3 4 5 6 Next >
Lazard Affirms Investor Confidence with $0.50 Quarterly Dividend Amidst Strong Financials
Lazard, Inc. (NYSE: LAZ), a prominent global financial advisory and asset management firm, has announced that its Board of Directors has declared a quarterly dividend of $0.50 per share on its... 
Via MarketMinute
Earnings Outlook For Lazard
 
Via Benzinga
Lazard (LAZ) Q3 Earnings: What To Expect
Financial advisory firm Lazard (NYSE:LAZ) will be reporting earnings this Thursday before the bell. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence World Trade
3 Stocks Under $50 with Warning Signs
Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and... 
Via StockStory
Earnings Scheduled For July 24, 2025
 
Via Benzinga
Lazard's Earnings: A Preview
 
Via Benzinga
Lazard's Earnings Outlook
 
Via Benzinga
2 Reasons to Sell LAZ and 1 Stock to Buy Instead
Lazard has been on fire lately. In the past six months alone, the company’s stock price has rocketed 40%, reaching $48.82 per share. This was partly due to its solid quarterly results, and the... 
Via StockStory
Topics Government World Trade
2 Profitable Stocks to Research Further and 1 We Avoid
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my... 
Via StockStory
Why Lazard (LAZ) Stock Is Trading Up Today
Shares of financial advisory firm Lazard (NYSE:LAZ) jumped 3.3% in the afternoon session after analyst firm Keefe, Bruyette & Woods maintained its "Outperform" rating on the stock, signaling continued... 
Via StockStory
Topics Economy
What 8 Analyst Ratings Have To Say About Lazard
 
Via Benzinga
Breaking Down Lazard: 8 Analysts Share Their Views
 
Via Benzinga
Lazard (LAZ) Stock Trades Up, Here Is Why
Shares of financial advisory firm Lazard (NYSE:LAZ) jumped 2.3% in the morning session after the company announced the appointment of Dr. Geoffrey Porges as a Managing Director in its Healthcare... 
Via StockStory
Topics Economy
Ecovyst Streamlines Focus As Technip Energies Snaps Up Catalysts Business
Ecovyst Inc. (NYSE: ECVT) to sell Advanced Materials & Catalysts division to Technip Energies (OTC: THNPY) for $556M, reshaping strategic focus. 
Via Benzinga
3 Unpopular Stocks We’re Skeptical Of
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps... 
Via StockStory
Wall Street Roars Back: Investment Banking Surges with M&A, IPOs, and a Hiring Spree
Wall Street's investment banking sector is experiencing a significant and widely anticipated rebound, signaling a renewed confidence across global financial markets. After a challenging period... 
Via MarketMinute
Topics Economy Government Initial Public Offering
What 7 Analyst Ratings Have To Say About Lazard
 
Via Benzinga
A Look Back at Investment Banking & Brokerage Stocks’ Q2 Earnings: Goldman Sachs (NYSE:GS) Vs The Rest Of The Pack
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Goldman Sachs (NYSE:GS) and the... 
Via StockStory
Recent Report Shows That Rep. French Hill Sold Up to $810K Worth of Blackstone Stock
 
Via Benzinga
6 Analysts Have This To Say About Lazard
 
Via Benzinga
Analyst Expectations For Lazard's Future
 
Via Benzinga
The Analyst Verdict: Lazard In The Eyes Of 6 Experts
 
Via Benzinga
LAZARD INC (NYSE:LAZ) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
When you look at LAZARD INC (NYSE:LAZ), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. 
Via Chartmill
Earnings Scheduled For April 25, 2025
 
Via Benzinga
Despite its growth, LAZARD INC (NYSE:LAZ) remains within the realm of affordability.
Uncover the potential of LAZARD INC, a growth stock reasonably priced. NYSE:LAZ is excelling in growth aspects, maintaining a healthy financial position, and still offers an attractive valuation. 
Via Chartmill
Forecasting The Future: 9 Analyst Projections For Lazard
 
Via Benzinga
Investors should take note of LAZARD INC (NYSE:LAZ), a growth stock that remains attractively priced.
NYSE:LAZ is scoring great on several growth aspects while it also shows decent health and profitability. At the same time it remains remains attractively priced. 
Via Chartmill
Hello Group, loanDepot, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
 
Via Benzinga
Investors should take notice of LAZARD INC (NYSE:LAZ)—it offers a great deal for the fundamentals it presents.
When you look at LAZARD INC (NYSE:LAZ), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. 
Via Chartmill
For those who appreciate growth without the sticker shock, LAZARD INC (NYSE:LAZ) is worth considering.
Discover LAZARD INC, an undervalued growth gem. NYSE:LAZ is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing valuation. 
Via Chartmill
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.